Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: beyond autoimmune insulin-dependent diabetes
Immune-mediated beta cell destruction is known to cause hyperglycemia in patients receiving immune checkpoint inhibitor (ICI) cancer therapy. However, it is uncommon, and little is known about the full spectrum of hyperglycemia in patients receiving ICIs. We aimed to characterize the prevalence and factors associated with hyperglycemia in patients treated with ICIs.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Amanda Leiter, Emily Carroll, Danielle Brooks, Jennifer Ben Shimol, Elliot Eisenberg, Juan P. Wisnivesky, Matthew D. Galsky, Emily J. Gallagher Source Type: research